Immunoprecise Short Long Term Debt Total from 2010 to 2024

IPA Stock  USD 1.28  0.09  6.57%   
Immunoprecise Antibodies' Short and Long Term Debt Total is increasing over the years with slightly volatile fluctuation. Overall, Short and Long Term Debt Total is expected to go to about 8.8 M this year. From 2010 to 2024 Immunoprecise Antibodies Short and Long Term Debt Total quarterly data regression line had arithmetic mean of  3,306,622 and r-squared of  0.79. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2002-10-31
Previous Quarter
9.6 M
Current Value
9.6 M
Quarterly Volatility
2.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunoprecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunoprecise main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.1 M, Interest Expense of 32.8 K or Total Revenue of 25 M, as well as many exotic indicators such as Price To Sales Ratio of 0.11, Dividend Yield of 0.0043 or Days Sales Outstanding of 0.39. Immunoprecise financial statements analysis is a perfect complement when working with Immunoprecise Antibodies Valuation or Volatility modules.
  
This module can also supplement Immunoprecise Antibodies' financial leverage analysis and stock options assessment as well as various Immunoprecise Antibodies Technical models . Check out the analysis of Immunoprecise Antibodies Correlation against competitors.
For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

Latest Immunoprecise Antibodies' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Immunoprecise Antibodies over the last few years. It is Immunoprecise Antibodies' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunoprecise Antibodies' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

Immunoprecise Short Long Term Debt Total Regression Statistics

Arithmetic Mean3,306,622
Geometric Mean965,176
Coefficient Of Variation91.00
Mean Deviation2,315,855
Median3,457,000
Standard Deviation3,008,965
Sample Variance9.1T
Range8.8M
R-Value0.89
Mean Square Error2T
R-Squared0.79
Slope598,679
Total Sum of Squares126.8T

Immunoprecise Short Long Term Debt Total History

20248.8 M
20238.4 M
20227.3 M
20212.5 M
20203.5 M
20194.5 M
20182.9 M

About Immunoprecise Antibodies Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immunoprecise Antibodies income statement, its balance sheet, and the statement of cash flows. Immunoprecise Antibodies investors use historical funamental indicators, such as Immunoprecise Antibodies's Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Although Immunoprecise Antibodies investors may use each financial statement separately, they are all related. The changes in Immunoprecise Antibodies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunoprecise Antibodies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunoprecise Antibodies Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunoprecise Antibodies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short and Long Term Debt Total8.4 M8.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:
Check out the analysis of Immunoprecise Antibodies Correlation against competitors.
For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
CEOs Directory
Screen CEOs from public companies around the world
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.42)
Revenue Per Share
0.939
Quarterly Revenue Growth
0.203
Return On Assets
(0.11)
Return On Equity
(0.26)
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.